Shenzhen Salubris Pharmaceuticals Co: Revenue and net profit rose on strong innovative product growth and robust cash flow

About this update from Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

Revenue grew 22.18% year-over-year to ¥3.00 billion, with net profit up 6.37% and strong cash flow. Innovative products drove growth, while R&D and hospital access investments continued to rise.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A